You are here

  • Home
  • Archive
  • Volume 21, Issue 1
  • Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Systematic review with meta analysis
Low to moderate quality evidence demonstrates the potential benefits and adverse events of cannabinoids for certain medical indications
  1. Kevin P Hill1,
  2. W Max Hurley-Welljams-Dorof2
  1. 1McLean Hospital/Harvard Medical School, Belmont, Massachusetts, USA;
  2. 2Division of Drug and Alcohol Abuse, McLean Hospital, Belmont, Massachusetts, USA
  1. Correspondence to Dr Kevin P Hill, Division of Drug and Alcohol Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; khill{at}mclean.harvard.edu

https://doi.org/10.1136/ebmed-2015-110264

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015;313:2456–73.OpenUrlCrossRefPubMed

    Context

    As of September 2015, 23 states and the District of Columbia in the USA legalised the medicinal use of marijuana, underscoring the need for physicians to understand the science underlying medical marijuana as well as the practical issues associated with it. For years policymakers, scientists and physicians alike have debated the potential risks associated with marijuana use.1 Now marijuana's utility as a treatment for certain medical indications has taken focus. Patients are turning to physicians to answer marijuana-related questions and to learn about its potential risks and benefits.2 This review examines the potential benefits along with associated adverse events (AEs) of cannabinoids, in different forms, for various …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.